5M2B
Yeast 20S proteasome with human beta5i (1-138) and human beta6 (97-111; 118-133) in complex with thiazole based inhibitor Ro19
Summary for 5M2B
| Entry DOI | 10.2210/pdb5m2b/pdb |
| Related | 5L5B |
| Descriptor | Proteasome subunit alpha type-2, Proteasome subunit beta type-4, Proteasome subunit beta type-8,Proteasome subunit beta type-5, ... (18 entities in total) |
| Functional Keywords | hydrolase-hydrolase inhibitor complex, proteasome, mutant, inhibitor, binding analysis, hydrolase/hydrolase inhibitor |
| Biological source | Homo sapiens (Human) More |
| Total number of polymer chains | 28 |
| Total formula weight | 732598.31 |
| Authors | Groll, M. (deposition date: 2016-10-12, release date: 2017-01-25, Last modification date: 2024-01-17) |
| Primary citation | Cui, H.,Baur, R.,Le Chapelain, C.,Dubiella, C.,Heinemeyer, W.,Huber, E.M.,Groll, M. Structural Elucidation of a Nonpeptidic Inhibitor Specific for the Human Immunoproteasome. Chembiochem, 18:523-526, 2017 Cited by PubMed Abstract: Selective inhibition of the immunoproteasome is a promising approach towards the development of immunomodulatory drugs. Recently, a class of substituted thiazole compounds that combine a nonpeptidic scaffold with the absence of an electrophile was reported in a patent. Here, we investigated the mode of action of the lead compound by using a sophisticated chimeric yeast model of the human immunoproteasome for structural studies. The inhibitor adopts a unique orientation perpendicular to the β5i substrate-binding channel. Distinct interactions between the inhibitor and the subpockets of the human immunoproteasome account for its isotype selectivity. PubMed: 28098422DOI: 10.1002/cbic.201700021 PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (2.7 Å) |
Structure validation
Download full validation report
